Antibodies

#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

The Discovery and Evolution of Antibody Formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent™ F1P HF as an alternative strategy for isolating next-generation… Read More

#Resources

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies #Webinar

What are the drivers and challenges in therapeutic antibody discovery?

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry.   The webinar will take place on… Read More

Webinar date:
Sponsored by Bio-Rad
#News

Antibodies
#Antibodies #Antibody drug conjugate (ADC) #Biologics #Therapeutic Antibodies

What are the drivers and challenges in therapeutic antibody discovery?

In this free webinar, hosted by DDW and sponsored by Bio-Rad, you will learn about the innovation taking place within the therapeutic antibody sector and what the current opportunities and challenges are for drug developers in the industry. You will hear from Aron Knickerbocker, CEO of Aulos Bioscience, and Martin… Read More

Webinar date:
Sponsored by Bio-Rad
#Webinars

#Antibodies #Monoclonal antibodies #Pandemic prevention #Pandemic response

Polyclonal and recombinant antibody development

Joerg Schuettrumpf, Chief Scientific Innovation Officer at Grifols, discusses advancements in antibody therapies, focusing on IgA, IgM, and recombinant polyclonal technologies to enhance treatment efficacy, scalability, and preparedness for global health challenges. IgA and IgM therapies The therapeutic antibody field is progressing rapidly, says Schuettrumpf, with key advances in broad-spectrum… Read More

#Exclusive Content

#Antibodies #Bispecific Antibodies #Interview #Oncology #Therapeutic Antibodies

Dual-targeted antibody innovations for cancer treatment

David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, speaks to Megan Thomas about innovation in therapeutic antibody development, in the context of the company’s accelerated development of a novel PD1/VEGFR2 bifunctional antibody planned to enter the clinic in 2025, designed as a dual-pathway, single agent, IgG therapy targeting… Read More

#Cancer Research #Exclusive Content

#Absci #AI / data analytics / healthtech / informatics #Antibodies #Artificial intelligence (AI) #Drug discovery #Drug targets #Interview #Machine learning

New podcast: The continued evidence of AI’s drug discovery value

This is the latest episode of the free DDW narrated podcast, titled “The continued evidence of AI’s drug discovery value”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “How generative AI could improve drug discovery” and “Can… Read More

#News

#Antibodies #Autoimmune disease #Collaboration #FcR Therapeutics #Grifols #Nanobodies

Partners to target autoimmune Fc receptors using nanobodies

Grifols and biotechnology startup, FcR Therapeutics, have agreed to collaborate on recombinant nanobodies to treat autoimmune diseases.  The nanobodies, which are small highly specialised antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of immune cells that… Read More

#Business & Investment #News

Mosquito
#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies #National Institutes of Health (NIH)

Researchers discover novel class of anti-malaria antibodies

A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published in Science.   Of the five species of… Read More

#News

IgE antibodies
#Antibodies #Bifunctional medicine #Cancer research #Funding #Investment #Ottimo Pharma

Bifunctional medicines to extend the lives of cancer patients

Ottimo Pharma has completed a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets. The round was led… Read More

#Business & Investment #Cancer Research #Editor's Choice #News

Bispecific antibodies
#Antibodies #Antibody engineering #Bispecific Antibodies #EpiBiologics #PEGS Europe

Data shows disease-selective extracellular protein degradation 

EpiBiologics presented new data demonstrating the unique capabilities of its EpiTAC platform at the 16th Annual PEGS Europe conference (November 5-7, 2024 in Barcelona, Spain) and the 2024 Antibody Engineering and will be presenting again at Therapeutics US conference (December 15-18, 2024 in San Diego, California).  … Read More

#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

One week to go: Discover next-generation antibody production

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

Learn how to produce high-affinity & specificity rabbit mAbs

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

Next-gen antibody discovery: Leveraging DNA immunisation

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

New webinar: Next-generation antibody discovery

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery

Next-gen antibody discovery: Leveraging DNA immunisation and single B-cell cloning for high-affinity & specificity rabbit mAbs

Watch this engaging and informative webinar on Fujifilm Wako’s groundbreaking advancements in rabbit monoclonal antibody discovery. Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with its proprietary single B-cell cloning technique, paving the way… Read More

Webinar date:
Supported by Fujifilm Wako
#Webinars

CT scans of the brain
#Alzheimer's #Antibodies #Biogen #Biologics #Eisai #Neurodegenerative disorders

Data demonstrate long-term effect of lecanemab in early Alzheimer’s

Lecanemab-irmb (Leqembi), an anti-amyloid beta (Aβ) protofibril antibody, continues to show benefit for early Alzheimer’s disease (AD) patients over three years, according to new trial results. Eisai and Biogen shared the latest findings at the Alzheimer’s Association International Conference (AAIC) 2024, held in Philadelphia. Read More

#News